Loading
Femasys Inc Stock: price and insider trades · United States
5 insiders bought €116k of shares over the last 90 days, the latest by Canning John Charles, filed 11 Aug 2026.
Femasys Inc: what insiders have been doing
Femasys Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 5 insiders published 5 filings.
The flow runs one way only: 5 insiders bought (5 purchases totalling €116k) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 3 senior executives, 1 finance chief and 1 chief executive among the declarants. The largest single trade was a purchase of €43k by Elefant Dov, published on 11 August 2026, equal to 0.23% of the market capitalisation.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 5 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 9 purchases and no sales.
In all, 5 purchases were made within 30 days of a purchase by another insider of the company. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 11 August 2026, 68 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
17
Thresholds
n/a
Buy Volume
€2M
9 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleDov Elefant1 buy
Jeffrey Gerald Mifek1 buy
Jeremy Alexander Sipos1 buy
John Charles Canning1 buy
Kathy Lee-Sepsick1 buy
Since the insiders bought
- -29.8%Entry US$2.35 · Close 16 Oct 2026 US$1.65
- -29.8%Entry US$2.35 · Close 16 Oct 2026 US$1.65
- -29.8%Entry US$2.35 · Close 16 Oct 2026 US$1.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.56
Analyst consensus
3 analysts1.67/5
US$10.00Target US$14.33(+819%)US$23.00
Income statement
RevenueUS$2.3M
Gross profitUS$1.4M62% margin
EBITDA-US$15.9M-693% margin
Net income-US$18.6M-812.3% margin
Valuation
PER (forward)-0.7x
P/Book1.2x
Beta-2.16
Balance sheet & cash
Market capUS$13.1M
Total debtUS$4.7M
Free Cash Flow-US$19.3M
Debt / Equity119%
Profitability & ownership
ROE-425.0%
ROA-84.2%
% insiders3.9%
% institutions47.3%
Last declaration on 11 August 2026
Declarations17 total
4,375 shares@ US$3.200.064% mcap100.0% of flowCommon StockSEC:0001140361-26-032320:0
Canonical exit: 5 Nov 2026 (T+90)
15,625 shares@ US$3.200.23% mcap71.3% of flowCommon StockSEC:0001140361-26-032317:0
Canonical exit: 5 Nov 2026 (T+90)
15,625 shares@ US$3.200.23% mcap58.7% of flowCommon StockSEC:0001140361-26-032314:0
Canonical exit: 5 Nov 2026 (T+90)
3,125 shares@ US$3.200.046% mcap100.0% of flowCommon StockSEC:0001140361-26-032324:0
Canonical exit: 5 Nov 2026 (T+90)
3,125 shares@ US$3.200.046% mcap100.0% of flowCommon StockSEC:0001140361-26-032336:0
Canonical exit: 5 Nov 2026 (T+90)
38,828 sharesCommon StockSEC:0001140361-25-033200:0
48,535 sharesCommon StockSEC:0001140361-25-033197:0
24,510 shares@ US$1.0222.3% of flowCommon stockSEC:0001140361-25-021412:0
19,608 shares@ US$1.0228.7% of flowCommon StockSEC:0001140361-25-021410:0
19,608 shares@ US$1.02100.0% of flowCommon StockSEC:0001140361-25-021411:0
34,314 shares@ US$1.0241.3% of flowCommon StockSEC:0001140361-25-021409:0
12,191 shares0Common StockSEC:0001140361-21-042254:0
3,219,795 shares0Common StockSEC:0001140361-21-042258:0
2,500 shares@ US$13.18100.0% of flowCommon StockSEC:0001140361-21-022188:0
Canonical exit: 16 Sept 2021 (T+90)
100,000 shares@ US$13.00100.0% of flowCommon StockSEC:0001140361-21-022197:0
Canonical exit: 20 Sept 2021 (T+90)
7,000 shares@ US$13.0077.7% of flowCommon StockSEC:0001140361-21-022194:0
Canonical exit: 20 Sept 2021 (T+90)
40,000 shares@ US$13.00100.0% of flowCommon StockSEC:0001140361-21-022190:0
Canonical exit: 20 Sept 2021 (T+90)
17 of 17 declarations
About Femasys Inc
Femasys Inc. (ticker FEMY) is a biomedical and medtech company listed on the NASDAQ in the United States (United States), with a focused franchise in women’s reproductive health. Incorporated in Delaware in 2004 and headquartered in Suwanee, Georgia, near Atlanta, the company addresses a specialized niche that has historically been underserved by large medtech groups. Its strategy is built around minimally invasive, in-office technologies designed to improve diagnosis and treatment in fertility and gynecological care, while reducing reliance on surgery, hormones, implants, or more cumbersome radiology-based procedures. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001339005/000114036126012375/femy-20251231.htm))
Femasys’ product portfolio is anchored by a set of patent-protected devices and product candidates. FemaSeed is positioned as an intratubal insemination solution for female infertility treatment. FemVue and FemCath are used for fallopian tube assessment and related reproductive diagnostics, while FemCerv is designed for endocervical tissue sampling. The company’s most strategically important program is FemBloc, a non-surgical, non-implant, non-hormonal permanent birth control solution that is being advanced through pivotal clinical development. Several of these products are already commercialized in the U.S. and select international markets, and the company has also been expanding its regulatory footprint abroad. ([d5bp8bijhhba2.cloudfront.net](https://d5bp8bijhhba2.cloudfront.net/pdf/55566050e58db1cc44e9f8278a1191a98df3c4bf320038a737406f6388cc3052.pdf))
Read moreShow less
From a competitive standpoint, Femasys is not a broad-platform healthcare company but a specialist innovator targeting large, underserved global market segments in reproductive health. That focus gives it a differentiated value proposition, particularly for clinicians and patients seeking office-based alternatives that may be simpler, safer, and less invasive than traditional options. At the same time, the company remains in the early-to-mid commercialization phase and carries the execution risks typical of small-cap medtech developers: limited operating history as a commercial business, continuing operating losses, and a dependence on product adoption, clinical progress, and outside financing. The latest annual filing also notes substantial doubt about the company’s ability to continue as a going concern, underscoring the financial risk profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001339005/000114036126012375/femy-20251231.htm))
Recent developments have been important. In 2024, Femasys secured EU MDR / CE Mark certification for multiple products, and it also received additional approvals in the U.K. for FemaSeed and certain diagnostic devices. In 2025, management highlighted clinical, regulatory, and commercial progress, and full-year 2025 revenue increased, primarily due to FemBloc sales. The company also said its cash position would fund operations into the third quarter of 2026 based on its current plan. For international investors, FEMY is therefore best viewed as a high-risk, high-optional-value women’s health platform with meaningful regulatory milestones, early commercialization traction, and a still-constrained balance sheet. ([ir.femasys.com](https://ir.femasys.com/news/news-details/2026/Femasys-Announces-Financial-Results-for-Year-Ended-December-31-2025-and-Provides-Corporate-Update/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
